|Bid||198.90 x 900|
|Ask||199.24 x 1100|
|Day's Range||196.15 - 201.90|
|52 Week Range||47.50 - 222.33|
|Beta (3Y Monthly)||2.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||278.25|
“I think this is a very exciting phase for the company to transition from the R&D; stage to (becoming) a commercial company,”said Reata's Manmeet Soni in an interview.
The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $505.1 million. Citigroup, Jefferies, SVB Leerink and Stifel acted as the joint book-running managers for the offering. Baird, Cantor and Ladenburg Thalmann acted as the co-managers for the offering.
A week ago, Reata Pharmaceuticals, Inc. (NASDAQ:RETA) came out with a strong set of third-quarter numbers that could...
The offering was upsized to 2,400,000 shares from the original offering size of 2,000,000 shares. The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $439,200,000. The offering is expected to close on November 18, 2019, subject to customary closing conditions.
Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 2,000,000 shares of its Class A common stock in an underwritten public offering pursuant to an existing shelf registration statement. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Citigroup, Jefferies, SVB Leerink and Stifel are acting as the joint book-running managers for the offering.
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -5.60% and 5.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...
PLANO, Texas, Nov. 12, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced financial.
Shares of Reata Pharmaceuticals were briefly halted late Monday just before the biotech company confirmed a recently reacquired kidney disease drug succeeded in a Phase 3 study.
Reata Pharmaceuticals Inc. shares were halted in the extended session Monday as the biotech drug developer reported positive results from a late-stage kidney disease treatment study. Reata shares were flat, following a 1% rise to close the regular session at $213.67. In a Phase 3 study, Reata said its drug bardoxolone treated patients with chronic kidney disease caused by Alport syndrome significantly better than a placebo in primary and secondary endpoints. Alport syndrome is a rare, genetic form of kidney disease that causes end-stage kidney failure in a majority of patients.
Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, announced today that the Phase 3 portion of the CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) caused by Alport syndrome met its primary and key secondary endpoints. After 48 weeks of treatment, patients treated with bardoxolone had a statistically significant improvement compared to placebo in mean estimated glomerular filtration rate (eGFR) of 9.50 mL/min/1.73 m2 (p
IRVING, Texas, Nov. 05, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results.
Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees during the first half of 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a […]
Biotech stocks saw some strength last week. Positive clinical readouts, a couple of M&A deals and hopes of drug companies clinching a broader opioid settlement agreement worked in favor of the sector. ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...
Reata Pharmaceuticals and Axsome Therapeutics each have had a terrific 2019, which helps offset the losing bets in this high-beta sector of the market.
Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.
Reata Pharmaceuticals soared early Tuesday on positive Phase 2 test results of a treatment for Friedreich's ataxia. The biotech recently reacquired omaveloxolone from AbbVie.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Synthesis Energy Systems (NASDAQ: SES ) shares ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 14.) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals ...
Reata Pharmaceuticals Inc. shares surged after hours Monday as the biotech company announced positive results from a clinical trial for a neuromuscular disorder treatment. Reata shares, which had been halted after hours, surged 33% in the extended session, after closing up 5% at $100.59 in Monday trading for a market cap of just over $3 billion. Compared to placebo, the company said a mid-stage study of its treatment omaveloxolone significantly improved symptoms of Friedreich's ataxia, a debilitating neuromuscular disease that results in loss of coordination, weakness and fatigue. There are currently no treatments approved by the Food and Drug Administration for the disease, which affects about 22,000 globally, the company said.